Buying Precription Drugs Online May Be Dangerous – Consumer Alert –
Drug Enforcement Administration Says
National Association of Boards of Pharmacy (NABP)
Warning
“The Canadian Pharmacy, Canadian/European Pharmacy”, “Canadian Healthcare” and “US Drugstore” are brands of one of the most disgusting illegal online pharmacy group well organized CRIMINAL OPERATION of all times. “GREED” is the driving force behind this operation. Don’t let them fool you. They will never send you any genuine drugs. If they ever send anything at all, it may consist of literally anything from sugar to wall plaster, and they certainly don’t care that you will endanger your health by taking those dangerous counterfeit drugs.
Behind The Online Pharmacy
Today a shadowy, transnational network of illicit drug manufacturers, traders, doctors, Web site operators, spammers and criminals makes up the online pharmacy world.
Buying Medication Online Can Be Safe
There are many options out there when it comes to buying medication online. We have looked at websites after websites. Some sites feature offshore pharmacies that do not require a prior prescription. Others feature licensed pharmacies that do require a prescription from your doctor.
Before making a purchase that can effect your health, we strongly recommend that you consult your physician & DO NOT self-medicate. Ordering medication online can be a safe, money-saving experience. When done through licensed online pharmacies that require a prescription, you can be assured that the medication you get is exactly what you need to treat your ailments.
From: FDA Center for Drug Evaluation and Research 
FDAlnternetPharmacyTaskForce-CDER@fda.hhs.gov
Date: November 16, 2009
WARNING LETTER
- approved-swiss-meds.com,
- buy-rx-today.com,
- direct-rx-refill.com,
- value-european-pharmacy.com,
- mypillsfinder.com
- dutyfreemeds.com
- swissmeds.com
- bestrxdeal.com
- happypharmacy.net
- european-pharm.com
and has determined that you are offering products for sale in violation of the Federal Food, Drug, and Cosmetic Act (the Act). These products include, but are not limited to, “Acomplia (Brand),” “Acomplia (Generic),” “Rimonabant,” “Viagra (Brand),” “Cialis (Brand),” and “Prozac (Generic).” We request that you immediately cease marketing violative products.
These products are drugs under section 201 (g) of the Act, 21 U.S.C. § 321 (g), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. Your marketing and distribution of these drugs violate various provisions of the Act, as described below:
Unapproved New Drugs
Your firm offers many unapproved new drugs including, but not limited to “Acomplia (Brand),” “Acomplia (Generic),” and “Rimonabant.” FDA is taking this action against your firm because of the inherent risk in buying unapproved prescription drugs. Unapproved drugs from unregulated sources do not have the same assurance of safety and effectiveness as drugs subject to FDA oversight and have been found to be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. For drugs that are regulated by FDA, FDA protections include rigorous scientific standards for prescription drug approval and label review for accuracy and completeness, manufacturing procedures and testing performed under closely controlled conditions at FDA-registered and inspected facilities. In addition, pharmacies and wholesalers who sell or distribute prescription drugs in the U.S. are licensed by the states. Unapproved new drugs delivered to the American public from unregulated sources may not be safe and effective.
Rimonabant (also marketed under the name Acomplia) was specifically rejected for FDA approval because it did not meet the statutory requirements for safety and effectiveness. In June 2007, the FDA Endocrinologic and Metabolic Drugs AdVisory Committee unanimously voted not to recommend approval of the drug because of increased risk of neurological and psychiatric side effects including seizures, depression, anxiety, insomnia, aggressiveness, and suicidal thoughts among patients. Accordingly, the “Acomplia (Brand),” “Acomplia (Generic)” and “Rimonabant” dispensed through your websites are “new drugs,” as defined by section 201 (p) of the Act, 21 U.S.C. § 321(p).
Under sections 301(d) and 505(a) of the Act, 21 U.S.C. §§ 331(d) and 355(a), a new drug may not be introduced or delivered for introduction into interstate commerce unless an FDA-approved application is in effect for it. Your sale of several products, including “Acomplia (Brand),”
“Acomplia (Generic),” and “Rimonabant” without approved applications violates these provisions of the Act.
Misbranded Drugs
Your websites offer products for sale without requiring that the products be dispensed under a prescription from a duly licensed practitioner, including, but not limited to “Viagra (Brand),” “Cialis (Brand),” and “Prozac (Generic).” Therefore, the drugs are misbranded under section 503(b)(1) of the Act, 21 U.S.C. § 353(b)(1), and are marketed in violation of sections 301 (a), 301 (b), and 301 (k) of such Act, 21 U.S.C. §§ 331 (a), 331 (b), and 331 (k).
Further, your websites offer products for sale and state that the products are in compliance with U.S. law. As noted above, your products are not in compliance with U.S. law in that they are offered for sale in violation of the Act. Therefore, these products are misbranded under section
502(a) of the Act, 21 U.S.C. § 352(a), because the labeling of the drugs is false and misleading.
The introduction or delivery for introduction into interstate commerce of these misbranded products violates section 301 (a) of the Act, 21 U.S.C. § 331 (a).
This letter is not intended to identify all of the ways in which your activities might be in violation of United States law. It is your responsibility to ensure that all products marketed by your firm are in compliance with the Act and its implementing regulations. You should take prompt action to correct the violations noted above. Failure to correct these violations promptly may result in regulatory action, including but not limited to, seizure and/or injunction without further notice.
Please notify this office in writing within 15 working days of receipt of this letter of any steps you have taken or will take to correct the noted violations and to prevent their recurrence. If the corrective action(s) cannot be completed within 15 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response should be sent to FDAlnternetPharmacyTaskForce-CDER@fda.hhs.gov. Please direct any inquiries concerning this letter to FDA’s Internet Pharmacy Task Force at FDAlnternetPharmacyTaskForceCDER@fda.hhs.gov or (301) 796-3110.
Sincerely,
/S/
Deborah M. Autor, Esq.
Director
Office of Compliance
Center for Drug Evaluation and Research
Cc:
PrivacyProtect.org, Domain Administrator
contact@privacyprotect.org
http://www.approved-swiss-meds.com
http://www.swissmeds.com
http://www.european-pharm.com
Laura Owens
PO Box 701
San Mateo, CA 94401
http://www.buy-rx-today.com
Gordon Mcleod
PO Box 701
San Mateo, CA 94401
http://www.direct-rx-refill.com
Chris Walsh
PO Box 701
San Mateo, CA 94401
http://www.value-european-pharmacy.com
http://www.mypillsfinder.com
Marilyn Strongin
PO Box 701
San Mateo, CA 94401
http://www.dutyfreemeds.net
Ric Deleon
21 Villamore Street
Manila, Manila 2700
Philippines 7542000
Jared Melchert
39915 Millbrook Way
Murrieta, California 92563
http://www.happypharmacy.net
Address lookup
| canonical name | value-european-pharmacy.com. |
| aliases | |
| addresses | 64.27.1.195 |
Domain Whois record
Queried whois.internic.net with “dom value-european-pharmacy.com”…
Domain Name: VALUE-EUROPEAN-PHARMACY.COM
Registrar: DYNADOT, LLC
Whois Server: whois.dynadot.com
Referral URL: http://www.dynadot.com
Name Server: NS1.DOMAIN-ADMIN-CENTRAL.COM
Name Server: NS2.DOMAIN-ADMIN-CENTRAL.COM
Status: clientTransferProhibited
Updated Date: 24-mar-2009
Creation Date: 24-mar-2009
Expiration Date: 24-mar-2010
Last update of whois database: Sat, 15 Aug 2009 14:51:25 UTC
Queried whois.dynadot.com with “value-european-pharmacy.com”…
Domain Name: value-european-pharmacy.com
Registered at http://www.dynadot.com
Record expires on 2010/03/24 UTC
Record created on 2009/03/24 UTC
Domain servers in listed order:
ns1.domain-admin-central.com
ns2.domain-admin-central.com
Last update of whois database: 2009/08/15 07:48:47 PST
Network Whois record
Queried whois.arin.net with “64.27.1.195”…
OrgName: CALPOP.COM, INC.
OrgID: CALPO-4
Address: 600 W. 7th Street
Address: Suite 360
City: Los Angeles
StateProv: CA
PostalCode: 90017
Country: US
NetRange: 64.27.0.0 – 64.27.31.255
CIDR: 64.27.0.0/19
OriginAS: AS7796, AS14542, AS23244
NetName: CALPOP-NETWORK
NetHandle: NET-64-27-0-0-1
Parent: NET-64-0-0-0-0
NetType: Direct Allocation
NameServer: NS1.CALPOP.COM
NameServer: NS2.CALPOP.COM
Comment:
RegDate: 2000-01-10
Updated: 2009-03-30
OrgAbuseHandle: CALPO-ARIN
OrgAbuseName: CalPOP Abuse
OrgAbusePhone: +1-213-627-1937
OrgAbuseEmail: abuse@calpop.com
OrgNOCHandle: CNO4-ARIN
OrgNOCName: CalPOP Network Operations
OrgNOCPhone: +1-213-627-1937
OrgNOCEmail: noc@calpop.com
OrgTechHandle: RH1217-ARIN
OrgTechName: Hoover, Richard
OrgTechPhone: +1-213-627-1937
OrgTechEmail: support@calpop.com
# ARIN WHOIS database, last updated 2009-08-14 20:00
DNS records
DNS query for 195.1.27.64.in-addr.arpa returned an error from the server: NameError
| name | class | type | data | time to live | |||||||||||||||
| value-european-pharmacy.com | IN | SOA |
|
1800s | (00:30:00) | ||||||||||||||
| value-european-pharmacy.com | IN | NS | ns1.domain-admin-central.com | 1800s | (00:30:00) | ||||||||||||||
| value-european-pharmacy.com | IN | NS | ns2.domain-admin-central.com | 1800s | (00:30:00) | ||||||||||||||
| value-european-pharmacy.com | IN | A | 64.27.1.195 | 1800s | (00:30:00) | ||||||||||||||
— end —
Drugs Online May Be Dangerous Says Drug Enforcement Administration 
scamFRAUDalert®Pharmacies Checker 